USE OF VONICOG ALFA: REPORTS OF PREGNANCIES OUTCOME IN TWO PATIENTS WITH TYPE 2 VON WILLEBRAND DISEASES (2VWD)

被引：0
|
作者：
Schell, B. [1 ]
Desprez, D. [2 ]
Sattler, L. [3 ]
de Raucourt, E. [4 ]
Flaujac, C. [1 ]
机构：
[1] Hop Andre Mignot Versailles, Sect Hemostase, Lab Biol Med, Le Chesnay, France
[2] Ctr Ressources & Competences Malad Hemorrag, Le Chesnay, France
[3] Ctr Hosp Reg Univ Strasbourg, Lab Hematol, Strasbourg, France
[4] Hop Andre Mignot Versailles, Ctr Ressources & Competences Malad Hemorrag, Le Chesnay, France
来源：
HAEMOPHILIA | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P215
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [1] Type 2A von Willebrand disease and systemic sclerosis: Vonicog alfa reduced gastrointestinal bleeding
    Korsten, Peter
    Wallbach, Manuel
    Binder, Claudia
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (07) : 1230 - 1234
  • [2] DDAVP in patients with von Willebrand disease (VWD) type 2N and phenotype compatible with VWD type 2N.
    Casais, P
    Farias, CE
    Meschengieser, SS
    Carballo, GA
    Kempfer, AC
    Grosso, S
    Lazzari, MA
    BLOOD, 2001, 98 (11) : 80B - 80B
  • [3] The use of two plasma derived factor VIII concentrates in type 2 a von Willebrand's disease (VWD).
    Hampton, KK
    Makris, M
    BLOOD, 2003, 102 (11) : 99B - 99B
  • [4] von Willebrand disease (vWD) type 2N in patients diagnosed to have haemophilia A or vWD type 1
    Cumming, AM
    Keeney, S
    Shanks, D
    Hay, CRM
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2682 - P2682
  • [5] Type 2N von Willebrand disease (VWD): one variant, two diseases? Analysis of the French cohort
    Goudemand, J.
    Zawadzki, C.
    Volot, F.
    Boisseau, P.
    Sigaud, M.
    Pouymayou, K.
    Itzhar, N.
    Caron, C.
    Fressinaud, E.
    Veyradier, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 118 - 119
  • [6] Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)
    Wang, Yi
    Ozen, Gulden
    Mellgard, Bjorn
    Marier, Jean Francois
    Barriere, Olivier
    Vasilinin, Grygoriy
    Bhattacharya, Indranil
    BLOOD, 2021, 138
  • [7] Biologic response to desmopressin (DDAVP) in 8 type 2 von Willebrand disease (vWD) patients
    Windyga, J.
    Bykowska, K.
    Baran, B.
    Stefanska, E.
    HAEMOPHILIA, 2008, 14 : 118 - 118
  • [8] Expression studies of von Willebrand factor missense mutations causing type 1 or type 2 von Willebrand disease (VWD)
    Yadegari, H.
    Driesen, J.
    Hambitzer, P.
    Pavlova, A.
    Oldenburg, J.
    HAEMOPHILIA, 2012, 18 : 195 - 196
  • [9] Genetic analyses of two patients with von Willebrand disease (VWD) type2B: implication of type 2B in the differential diagnosis for thrombocytopenic patients
    Sanda, N.
    Tanaka, R.
    Kishimoto, M.
    Suzuki, N.
    Kunishima, S.
    Takatsu, M.
    Matsumoto, H.
    Nakamura, S.
    Matsushita, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 946 - 947
  • [10] A comparison of two coagulation factor concentrates in type 2A and acquired von Willebrand's disease (VWD).
    Morley, NJ
    Makris, M
    Hampton, KK
    BLOOD, 2002, 100 (11) : 494A - 494A
12345